[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021012277A - Agonista multireceptor y uso medico del mismo. - Google Patents

Agonista multireceptor y uso medico del mismo.

Info

Publication number
MX2021012277A
MX2021012277A MX2021012277A MX2021012277A MX2021012277A MX 2021012277 A MX2021012277 A MX 2021012277A MX 2021012277 A MX2021012277 A MX 2021012277A MX 2021012277 A MX2021012277 A MX 2021012277A MX 2021012277 A MX2021012277 A MX 2021012277A
Authority
MX
Mexico
Prior art keywords
receptor
receptor agonist
medical use
glp
insulin
Prior art date
Application number
MX2021012277A
Other languages
English (en)
Inventor
Rudi Bao
Xiao Liu
Xiaolei Wang
Lei Wang
Haiqing Hua
Fangzhou Wu
Ran Wu
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of MX2021012277A publication Critical patent/MX2021012277A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una serie de composiciones farmacéuticas que contienen compuestos agonistas duales de polipéptidos y sales farmacéuticamente aceptables de los mismos, en donde los mismos tienen efectos agonistas duales en un receptor de péptido similar a glucagón tipo 1 (GLP-1) humano y un receptor de polipéptido insulinotrópico dependiente de glucosa (GIP) de sangre humana, y se pueden utilizar para tratar diabetes no dependiente de insulina, diabetes insulinodependiente, obesidad y otras enfermedades relacionadas.
MX2021012277A 2019-04-11 2020-04-10 Agonista multireceptor y uso medico del mismo. MX2021012277A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910290162 2019-04-11
CN201911120906 2019-11-15
PCT/CN2020/084247 WO2020207477A1 (zh) 2019-04-11 2020-04-10 Glp-1和gip受体双重激动剂化合物及其应用

Publications (1)

Publication Number Publication Date
MX2021012277A true MX2021012277A (es) 2021-11-12

Family

ID=72752204

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012277A MX2021012277A (es) 2019-04-11 2020-04-10 Agonista multireceptor y uso medico del mismo.

Country Status (11)

Country Link
US (1) US20220168396A1 (es)
EP (1) EP3954701A4 (es)
JP (1) JP7577678B2 (es)
KR (1) KR20210149747A (es)
CN (1) CN112351994B (es)
AU (1) AU2020256648A1 (es)
BR (1) BR112021020071A2 (es)
CA (1) CA3136163A1 (es)
MX (1) MX2021012277A (es)
TW (1) TW202104253A (es)
WO (1) WO2020207477A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230018395A (ko) * 2020-05-29 2023-02-07 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 Glp-1 및 gip 수용체 둘 모두에 대한 이중 작용제 화합물 및 이의 적용
MX2023000303A (es) * 2020-07-22 2023-02-09 Novo Nordisk As Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
KR20230083294A (ko) 2020-09-30 2023-06-09 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩타이드 접합체 및 사용 방법
CN114617956B (zh) * 2020-12-10 2023-10-03 江苏中新医药有限公司 一种高效降糖的蛋白质药物
WO2022199629A1 (zh) * 2021-03-25 2022-09-29 博瑞生物医药(苏州)股份有限公司 Gip和glp-1的双受体激动剂、药物组合物及用途
US20240150425A1 (en) * 2021-03-25 2024-05-09 Brightgene Bio-Medical Technology Co., Ltd. Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
JP2024522196A (ja) * 2021-06-09 2024-06-11 ザ スクリプス リサーチ インスティテュート 長時間作用型デュアルgip/glp-1ペプチドコンジュゲートおよび使用方法
CN115521368B (zh) * 2021-06-25 2024-08-23 江苏鸿永医药技术有限公司 毒蜥外泌肽-4衍生物
KR20240109258A (ko) * 2021-11-12 2024-07-10 푸지엔 셩디 파마슈티컬 컴파니 리미티드 Glp-1 수용체와 gip 수용체 이중 작용제의 약학적 조성물 및 이의 용도
AU2022401780A1 (en) * 2021-12-01 2024-07-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN116023444B (zh) * 2022-08-12 2023-08-01 重庆宸安生物制药有限公司 一种gip和glp-1双受体激动剂多肽化合物及其应用
TW202412835A (zh) * 2022-09-23 2024-04-01 大陸商博瑞生物醫藥(蘇州)股份有限公司 一種glp-1和gip雙受體激動劑藥物組合物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
NZ589847A (en) 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2010142665A1 (en) * 2009-06-11 2010-12-16 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
PE20120914A1 (es) 2009-06-16 2012-08-22 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
EP2654773B1 (en) 2010-12-22 2018-10-03 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
DK2694095T3 (en) * 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
KR102002783B1 (ko) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
SG11201407137PA (en) * 2012-05-03 2014-11-27 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
CN103861089B (zh) * 2012-12-17 2019-06-28 江苏豪森药业集团有限公司 Glp-1类似物的衍生物或其可药用盐注射液及其制备方法和用途
EP3400957A1 (en) * 2012-12-21 2018-11-14 Sanofi Functionalized exendin-4 derivatives
CN106029087A (zh) * 2013-12-20 2016-10-12 印第安纳大学研究及科技有限公司 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline

Also Published As

Publication number Publication date
CA3136163A1 (en) 2020-10-15
KR20210149747A (ko) 2021-12-09
JP7577678B2 (ja) 2024-11-05
AU2020256648A1 (en) 2021-11-04
WO2020207477A1 (zh) 2020-10-15
JP2022527803A (ja) 2022-06-06
EP3954701A4 (en) 2023-09-06
US20220168396A1 (en) 2022-06-02
EP3954701A1 (en) 2022-02-16
CN112351994A (zh) 2021-02-09
BR112021020071A2 (pt) 2021-12-14
TW202104253A (zh) 2021-02-01
WO2020207477A9 (zh) 2020-11-26
CN112351994B (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
MX2021012277A (es) Agonista multireceptor y uso medico del mismo.
MY197569A (en) Gip/glp1 co-agonist compounds
Prasad-Reddy et al. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Russell‐Jones et al. Recent advances in incretin‐based therapies
Scott Linagliptin: in type 2 diabetes mellitus
Bailey et al. Treatment of type 2 diabetes: future approaches
MX2022014368A (es) Compuesto de agonista doble para receptores de glp-1 y gip y aplicacion del mismo.
Barnett et al. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy
Terauchi et al. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study
CN112512633A (zh) 使用gip/glp1共激动剂用于治疗的方法
MX2022009149A (es) Compuestos coagonistas de gip/glp1.
Waldrop et al. Incretin-based therapy for diabetes: what a cardiologist needs to know
Unger Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes
Cyganek et al. Liraglutide therapy in Prader-Willi syndrome.
Pizzimenti et al. Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database.
PH12017501662A1 (en) Treatment type 2 diabetes mellitus patients
JP2016522241A5 (es)
Marroquin‐Harris et al. Aspiration risk with glucagon‐like peptide 1 (GLP‐1) agonists.
Engel et al. Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin
Sheffield et al. Off‐label use of exenatide for the management of insulin‐resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection
MX2023009550A (es) Antagonistas del receptor del peptido-1 tipo glucagon.
Horowitz et al. DPP-4 inhibition and the known unknown
Chaplin DPP‐4/SGLT2 inhibitor combined therapy for type 2 diabetes
Kenny et al. GLP-1 receptor agonist and basal insulin co-therapy in type 2 diabetes: clinical evidence and practicalities of use
Chan et al. Glucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know